Eli Lilly Stock Rises 1.61%, Valued at $9 Billion, on Tirzepatide DDC Nomination

Eli Lilly's stock, trading under the ticker symbol $LLY, has experienced a notable increase in value, rising 1.61% in premarket trading on December 4, 2024. This uptick follows the nomination of its drug Tirzepatide for the Drug Development Committee (DDC) list. Over the past eight to nine sessions, the stock has regained approximately $100, reflecting a significant recovery. Analysts have described $LLY as an 'unbelievable' trade recently, with expectations that the stock could continue to rise towards the higher end of its trading range. The market sentiment remains positive as several pharmaceutical companies also show gains ahead of the Citi Healthcare conference.